Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening.
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies
Patti, Francesco;
2021-01-01
Abstract
Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
effectiveness of natalizumab vs fingolimod.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
1.67 MB
Formato
Adobe PDF
|
1.67 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
